trending Market Intelligence /marketintelligence/en/news-insights/trending/87nan6ysjlj_vjvel5q7za2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Mylan acquires rights to 2 Novartis respiratory drugs in $463M deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Mylan acquires rights to 2 Novartis respiratory drugs in $463M deal

Mylan NV said it acquired the global rights to two Novartis AG respiratory drugs in a deal valued at about $463 million.

Novartis' TOBI Podhaler and TOBI solution are meant to treat cystic fibrosis, a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time.

Mylan expects to settle approximately $240 million of the deal value this year.

The acquisition strengthens Mylan's portfolio of respiratory drugs.